Evidence map›Paper›PMID 42326839›Full record

ArticleThe Lancet regional health. Western Pacific2026

High-dose, short-course primaquine after point-of-care G6PD testing for the radical cure of

Liony Fransisca, Maria Ome-Kaius, Moses Laman, Jeanne Rini Poespoprodjo, Ayodhia P Pasaribu, Inge Sutanto, Mary Malai, Erni Nelwan, Jacklyn Adella, Cynthia Abegini and 39 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors.

Liony FransiscaYayasan Pengembangan Kesehatan dan Masyarakat Papua, Timika, Papua, Indonesia.
Maria Ome-KaiusPapua New Guinea Institute of Medical Research, Port Moresby, Papua New Guinea.
Moses LamanPapua New Guinea Institute of Medical Research, Port Moresby, Papua New Guinea.
Jeanne Rini PoespoprodjoYayasan Pengembangan Kesehatan dan Masyarakat Papua, Timika, Papua, Indonesia.
Ayodhia P PasaribuDepartment of Pediatrics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Inge SutantoDepartment of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Mary MalaiPapua New Guinea Institute of Medical Research, Port Moresby, Papua New Guinea.
Erni NelwanDepartment of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Jacklyn AdellaGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Cynthia AbeginiPapua New Guinea Institute of Medical Research, Port Moresby, Papua New Guinea.
Framita AinurTridarma Healthcare Empowerment Foundation, Medan, Sumatera Utara, Indonesia.
Yolyne AmdaraPapua New Guinea Institute of Medical Research, Port Moresby, Papua New Guinea.
Sherley AngelineHanura Primary Health Centre (Puskesmas), Lampung, Indonesia.
Katelyn BrownCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
Faustina H BurdamYayasan Pengembangan Kesehatan dan Masyarakat Papua, Timika, Papua, Indonesia.
Ella CurryGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Martin DaimenMadang Provincial Health Authority, Papua New Guinea.
Paul DalyBurnet Institute, Melbourne, Victoria, Australia.
Thy DoMedicines for Malaria Venture, Geneva, Switzerland.
Annie DoriBurnet Institute, Melbourne, Victoria, Australia.
Nicholas M DouglasGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Heike HuegelMedicines for Malaria Venture, Geneva, Switzerland.
Azkarunia P HutagalungTridarma Healthcare Empowerment Foundation, Medan, Sumatera Utara, Indonesia.
Elodie JambertMedicines for Malaria Venture, Geneva, Switzerland.
Vincent JimantoTridarma Healthcare Empowerment Foundation, Medan, Sumatera Utara, Indonesia.
Vali KaroDepartment of Infectious Diseases, Christchurch Hospital, Te Whatu Ora Waitaha, Christchurch, New Zealand.
Enny KenangalemYayasan Pengembangan Kesehatan dan Masyarakat Papua, Timika, Papua, Indonesia.
Trevor KelebiDepartment of Medicine, University of Otago, Christchurch, New Zealand.
Jacob KisombNational Malaria Control Program, Papua New Guinea National Department of Health, Papua New Guinea.
Ida LaksonoCentre for Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Grant LeeGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Benedikt LeyGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Kylie MannionGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Julius PlinduoNational Research and Innovation Agency (BRIN), Jakarta, Indonesia.
Irene PukaiPapua New Guinea Institute of Medical Research, Port Moresby, Papua New Guinea.
Adela PutriHanura Primary Health Centre (Puskesmas), Lampung, Indonesia.
Megha RajasekharCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
Sharol RonkentouPapua New Guinea Institute of Medical Research, Port Moresby, Papua New Guinea.
Evelien RosensBurnet Institute, Melbourne, Victoria, Australia.
Vanessa S SakalidisGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Ari SatyagrahaNational Research and Innovation Agency (BRIN), Jakarta, Indonesia.
Julie A SimpsonCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
Minerva TheodoraIndonesian National Malaria Control Program, Jakarta, Indonesia.
Reynold UbraMimika Health Office, Timika, Papua, Indonesia.
Norman VakoreEast New Britain Provincial Health Authority, Papua New Guinea.
Tanyaporn WansomChayun Consulting, Bangkok, Thailand.
Stephan DuparcMedicines for Malaria Venture, Geneva, Switzerland.
Leanne J RobinsonBurnet Institute, Melbourne, Victoria, Australia.
Ric N PriceGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: High total dose primaquine (PQ 7 mg/kg) over 7 days can improve treatment adherence and reduce Methods: Patients with Findings: Between October 2023 and September 2024, 800 patients were enrolled: 626 (78.3%) received PQ7, 148 (18.5%) PQ14, and 26 (3.3%) PQ8W. Of those patients who did not withdraw, 97.8% (773/790) were followed up on day 3 and 97.7% (765/783) on day 7. A total of 27 adverse events of special interest (AESIs) were reported in 26 patients; the risk of an AESI was 2.7% (17/626) of patients treated with PQ7, 4.1% (6/148) of patients treated with PQ14 and 11.5% (3/26) of patients treated with PQ8W. Overall, 24 AESIs (88.9%) were related to haemolysis, with the majority (n = 21) due to a fall in haemoglobin >3 g/dL, all without clinical compromise. Serious adverse events (SAEs) occurred in 16 (2.0%) patients, mostly gastrointestinal intolerance (68.8%; 11/16) in patients receiving PQ7. Of the 626 patients treated with PQ7, 9 (1.4%) experienced SAEs that were probably or possibly related to primaquine. Interpretation: The implementation of G6PD testing to guide primaquine treatment of patients with Funding: UNITAID and Australian National Health and Medical Research Council.

Indexed as

G6PD testingPharmacovigilancePlasmodium vivaxPrimaquineRadical cure

Identifiers

PMID42326839
PMCPMC13276568

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.